Cannabis storefronts and youth - what the evidence shows

At MHYP, our local community is at the heart of everything we do. We know that positive outcomes are possible when we share the same goals, and that shared goals often start with shared understanding of the facts.

Over the past decade, the facts around adolescent cannabis use and the impact of commercial cannabis sales have become more clear. In the 8 years since the first recreational cannabis storefront opened in California, we have seen a dramatic change in cannabis products and their impact.

One fact that hasn’t changed, however, is that Marin County continues to have one of the highest rates of adolescent cannabis use in California. Marin County 11th graders reported using cannabis in the past 30 days at a rate which is nearly four times the statewide average. A long history of normalized use and other risk factors have kept these rates stubbornly high. Yet today these rates exist alongside far more potent, commercially engineered products. 

The cannabis sold in California storefronts today is not the same product from a generation ago. THC potency has tripled since the mid-1990s, and peer-reviewed research confirms that higher potency is directly associated with greater risk of dependence and psychosis. Researchers have also documented that the cannabis industry has adopted many of the same strategies used by Big Tobacco: engineering products to appeal to young consumers, aggressive marketing, and lobbying against public health protections. Unlike alcohol or pharmaceuticals, no federal regulatory body currently sets safety standards, potency limits, or marketing restrictions for cannabis products sold in California storefronts.

To date, all jurisdictions in Marin have resisted the industry push for recreational storefronts. This cautious approach, based on the precautionary principle, has proven to be the best path in light of what we know today. Large-scale peer-reviewed studies of Kaiser Permanente patients in Northern California show clearly that storefront retail drives higher use. Jurisdictions without storefronts saw 21% less problematic adolescent cannabis use and 14% less adolescent cannabis use overall compared to jurisdictions that allowed storefronts. Adolescents in jurisdictions without storefronts had half the rate of diagnosed psychotic disorders compared to those where storefronts were allowed. 

These are not projections or models. They are observed outcomes from real patients, in real Northern California communities, studied in peer-reviewed journals.

The second body of evidence is equally clear: cannabis use, particularly among adolescents, is linked to serious, diagnosed health conditions. These are not theoretical risks. They are clinical outcomes documented in large patient populations and confirmed across multiple independent studies.

A study of nearly 500,000 Northern California teens found that those who used cannabis had double the risk of psychotic or bipolar disorder by age 25, and a 34% higher risk of depression, even after excluding any prior mental illness. That last point is significant: the elevated risk was not explained by any predisposition. 

A major meta-analysis reached similar conclusions, finding that adolescent cannabis users had 37% higher odds of major depression and significantly elevated risk of suicidal ideation and suicide attempts in young adulthood. Frequent users faced nearly four times the risk of schizophrenia or other psychotic disorders, with a confirmed dose-response relationship. The more cannabis used, the greater the risk.

The research does not require much interpretation. It shows, plainly, that the presence of cannabis storefronts in a community is associated with higher rates of use, particularly among teens, and that higher rates of use produce measurable harm. 

Marin's adolescent use rates are already far above state averages. Local decisions about retail storefronts are not abstract. They have documented consequences for the health of our neighbors, our children, and our community. As a community, let's commit to staying informed and prioritizing safer environments for ourselves and our children.

Sources

1. California Healthy Kids Survey (CHKS). Past 30-day marijuana use, 11th grade: Marin County 22%, Novato Unified 18%, California 6% (2023–25). CalSCHLS. calschls.org/my-surveys/f882f1e2-dfc0-4448-b90b-f49cef6e6d3f/

2. ElSohly MA, Mehmedic Z, Foster S, et al. "Changes in Cannabis Potency Over the Last 2 Decades (1995–2014)." Biological Psychiatry. 2016;79(7):613–619; and ElSohly MA, Chandra S, Radwan M, et al. "A Comprehensive Review of Cannabis Potency in the United States in the Last Decade." Biol Psychiatry Cogn Neurosci Neuroimaging. 2021;6(6):603–606.

3. Freeman TP, Craft S, Wilson J, et al. "Association of Cannabis Potency with Mental Ill Health and Addiction: A Systematic Review." Lancet Psychiatry. 2022;9(9):736–750.

4. Dewhirst T. "'Beyond Nicotine' Marketing Strategies: Big Tobacco Diversification into the Vaping and Cannabis Product Sectors." Tobacco Control. 2023;32(3):402–404.

5. Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2024 National Survey on Drug Use and Health. HHS Publication No. PEP25-07-007, NSDUH Series H-60. Rockville, MD: SAMHSA, 2025. 

6. Young-Wolff KC, Asera A, Padon AA, et al. "Association of Local Cannabis Policy and Retail Availability With Cannabis Use and Problematic Cannabis Use Among Adolescents in Northern California." American Journal of Public Health. 2024;114(S8):S654–S663.

7. Silver LD, Slama NE, Dong H, et al. "Associations of Local Cannabis Policy and Retail Availability in Northern California with Adverse Adolescent Mental Health Outcomes." Substance Use and Misuse. 2025;60(10):1571–1576.

8. Young-Wolff KC, Cortez CA, Alexeeff SE, et al. "Adolescent Cannabis Use and Risk of Psychotic, Bipolar, Depressive, and Anxiety Disorders." JAMA Health Forum. 2026;7(2):e256839.

9. Gobbi G, Atkin T, Zytynski T, et al. "Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-Analysis." JAMA Psychiatry.2019;76(4):426–434.

10. Maffre Maviel G, Somma C, Davisse-Paturet C, Airagnes G, Melchior M. "The Role of Depression in the Relationship Between Cannabis Use and Suicidal Behaviours: A Systematic Review and Meta-Analysis." Drug and Alcohol Dependence. 2025;273:112714.

11. Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. "Meta-Analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis." Schizophrenia Bulletin. 2016;42(5):1262–1269.

12. Robinson T, Ali MU, Easterbrook B, Hall W, Jutras-Aswad D, Fischer B. "Risk-Thresholds for the Association Between Frequency of Cannabis Use and the Development of Psychosis: A Systematic Review and Meta-Analysis." Psychological Medicine. 2023;53(9):3858–3868.